Your session is about to expire
← Back to Search
Cognitive Remediation + tDCS for Mental Health Disorders in Seniors (CREAtE Trial)
N/A
Waitlist Available
Led By Angela Golas, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 50 years and above. The rationale of age cutoff of 50 is that this age is considered a typical geriatric age cutoff especially for people with severe mental illness
Be older than 18 years old
Must not have
Having any contraindication to tDCS including: the presence of a skin disease, the presence of a pacemaker, implanted brain medical devices, the presence of any metal in the head or suffering from any unstable medical condition or illness that could increase the risk of stimulation (ie. epilepsy)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, after 8 week induction phase, and annually until study completion (12, 24, 36, 48, 60 months after baseline)
Summary
This trial will assess the effects of an 8-week course of cognitive remediation (CR) training among seniors with mental health conditions, followed by monthly boosters, to see if it can improve their lives and help them live independently.
Who is the study for?
This trial is for seniors aged 50+ with mental health conditions who are stable, haven't been hospitalized for psychiatric reasons in the last 3 months, and haven't changed their psychotropic meds in the last month. They must be able to see, hear well enough to participate, speak English, and give informed consent.
What is being tested?
The study tests an 8-week daily cognitive remediation (CR) training with monthly boosters over up to five years. It also examines if brain stimulation using tDCS can enhance CR's effectiveness. Participants will be randomly assigned to active or sham (fake) tDCS groups.
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site on the scalp, itching, tingling during application, headache or fatigue after treatment. Cognitive Remediation typically does not have physical side effects but could cause temporary mental fatigue.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 50 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I don't have skin diseases, pacemakers, metal in my head, brain devices, or conditions like epilepsy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, after 8 week induction phase, and annually until study completion (12, 24, 36, 48, 60 months after baseline)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, after 8 week induction phase, and annually until study completion (12, 24, 36, 48, 60 months after baseline)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Cognition
Change in Falls Risk using FROP-Com
Change in Falls Risk using PPA
+2 moreSecondary study objectives
Personal Support Workers Delivery of Intervention
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Cognitive Remediation and Active Transcranial Direct Current StimulationActive Control1 Intervention
Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
Group II: Cognitive Remediation and Sham Transcranial Direct Current StimulationPlacebo Group1 Intervention
CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
Find a Location
Who is running the clinical trial?
Centre for Addiction and Mental HealthLead Sponsor
372 Previous Clinical Trials
83,330 Total Patients Enrolled
2 Trials studying Mental Health Disorders
410 Patients Enrolled for Mental Health Disorders
LOFT Community ServicesUNKNOWN
3 Previous Clinical Trials
475 Total Patients Enrolled
Angela Golas, MDPrincipal InvestigatorCentre for Addiction and Mental Health
2 Previous Clinical Trials
52 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 50 years old or older.I don't have skin diseases, pacemakers, metal in my head, brain devices, or conditions like epilepsy.I have not had electroconvulsive therapy in the last 6 months.I can and am willing to communicate in English.My gender identity does not limit my participation.You have been diagnosed with any disorder according to the DSM-V guidelines.
Research Study Groups:
This trial has the following groups:- Group 1: Cognitive Remediation and Active Transcranial Direct Current Stimulation
- Group 2: Cognitive Remediation and Sham Transcranial Direct Current Stimulation
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger